334 related articles for article (PubMed ID: 1900222)
1. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion.
Haskel EJ; Prager NA; Sobel BE; Abendschein DR
Circulation; 1991 Mar; 83(3):1048-56. PubMed ID: 1900222
[TBL] [Abstract][Full Text] [Related]
2. Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and platelets.
Prager NA; Torr-Brown SR; Sobel BE; Abendschein DR
J Am Coll Cardiol; 1993 Jul; 22(1):296-301. PubMed ID: 8509554
[TBL] [Abstract][Full Text] [Related]
3. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis.
Nicolini FA; Lee P; Rios G; Kottke-Marchant K; Topol EJ
Circulation; 1994 Apr; 89(4):1802-9. PubMed ID: 8149546
[TBL] [Abstract][Full Text] [Related]
4. Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation.
Yasuda T; Gold HK; Leinbach RC; Yaoita H; Fallon JT; Guerrero L; Napier MA; Bunting S; Collen D
Circulation; 1991 Mar; 83(3):1038-47. PubMed ID: 1900221
[TBL] [Abstract][Full Text] [Related]
5. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
[TBL] [Abstract][Full Text] [Related]
6. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
Yao SK; Ober JC; Ferguson JJ; Anderson HV; Maraganore J; Buja LM; Willerson JT
Circulation; 1992 Dec; 86(6):1993-9. PubMed ID: 1451271
[TBL] [Abstract][Full Text] [Related]
7. Reocclusion after thrombolysis: a problem solved by hirudin?
Rübsamen K; Eschenfelder V
Blood Coagul Fibrinolysis; 1991 Feb; 2(1):97-100. PubMed ID: 1773004
[TBL] [Abstract][Full Text] [Related]
8. Thrombin inhibition enhances tissue-type plasminogen activator-induced thrombolysis and delays reocclusion.
Yao SK; McNatt J; Anderson HV; Eidt J; Cui KX; Golino P; Glas-Greenwalt P; Maraganore J; Buja LM; Willerson JT
Am J Physiol; 1992 Feb; 262(2 Pt 2):H374-9. PubMed ID: 1539695
[TBL] [Abstract][Full Text] [Related]
9. Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis.
Martin U; Dörge L; Fischer S
Br J Pharmacol; 1996 May; 118(2):271-6. PubMed ID: 8735626
[TBL] [Abstract][Full Text] [Related]
10. Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein IIb/IIIa receptors.
Haskel EJ; Adams SP; Feigen LP; Saffitz JE; Gorczynski RJ; Sobel BE; Abendschein DR
Circulation; 1989 Dec; 80(6):1775-82. PubMed ID: 2513145
[TBL] [Abstract][Full Text] [Related]
11. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
Mruk JS; Zoldhelyi P; Webster MW; Heras M; Grill DE; Holmes DR; Fuster V; Chesebro JH
Circulation; 1996 Feb; 93(4):792-9. PubMed ID: 8641009
[TBL] [Abstract][Full Text] [Related]
12. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.
Cannon CP; McCabe CH; Henry TD; Schweiger MJ; Gibson RS; Mueller HS; Becker RC; Kleiman NS; Haugland JM; Anderson JL
J Am Coll Cardiol; 1994 Apr; 23(5):993-1003. PubMed ID: 8144799
[TBL] [Abstract][Full Text] [Related]
13. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.
Sitko GR; Ramjit DR; Stabilito II; Lehman D; Lynch JJ; Vlasuk GP
Circulation; 1992 Feb; 85(2):805-15. PubMed ID: 1735171
[TBL] [Abstract][Full Text] [Related]
14. Blockade of platelet membrane glycoprotein Ib receptors delays intracoronary thrombogenesis, enhances thrombolysis, and delays coronary artery reocclusion in dogs.
Yao SK; Ober JC; Garfinkel LI; Hagay Y; Ezov N; Ferguson JJ; Anderson HV; Panet A; Gorecki M; Buja LM
Circulation; 1994 Jun; 89(6):2822-8. PubMed ID: 8205697
[TBL] [Abstract][Full Text] [Related]
15. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
Chen LY; Nichols WW; Mattsson C; Teger-Nilson AC; Wallin R; Saldeen TG; Mehta JL
Cardiovasc Res; 1995 Dec; 30(6):866-74. PubMed ID: 8746200
[TBL] [Abstract][Full Text] [Related]
16. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
Przyklenk K; Kloner RA
Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
[TBL] [Abstract][Full Text] [Related]
17. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-hirudin.
Rote WE; Mu DX; Bates ER; Nedelman MA; Lucchesi BR
J Cardiovasc Pharmacol; 1994 Feb; 23(2):203-11. PubMed ID: 7511748
[TBL] [Abstract][Full Text] [Related]
18. Coronary thrombosis/thrombolysis in pigs: effects of heparin, ASA, and the thrombin inhibitor inogatran.
Uriuda Y; Wang QD; Hatori N; Nordlander R; Sjöquist PO; Mattsson C; Rydén L
J Pharmacol Toxicol Methods; 1998 Mar; 39(2):81-9. PubMed ID: 9694166
[TBL] [Abstract][Full Text] [Related]
19. Effects of heparin, aspirin and a synthetic platelet glycoprotein IIb-IIIa receptor antagonist (Ro 43-5054) on coronary artery reperfusion and reocclusion after thrombolysis with tissue-type plasminogen activator in the dog.
Roux SP; Tschopp TB; Kuhn H; Steiner B; Hadváry P
J Pharmacol Exp Ther; 1993 Jan; 264(1):501-8. PubMed ID: 8423548
[TBL] [Abstract][Full Text] [Related]
20. Systemic lysis protects against the effects of platelet activation during coronary thrombolysis.
Fitzgerald DJ; Hanson M; FitzGerald GA
J Clin Invest; 1991 Nov; 88(5):1589-95. PubMed ID: 1939647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
